We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Preventing Rheumatoid Arthritis Requires a Mixed Population of Regulatory T-cells

By LabMedica International staff writers
Posted on 23 May 2012
A recent article discussed the latest thinking regarding the molecular aspects of how the immune system guards itself from the development of autoimmune disorders such as rheumatoid arthritis and why this system sometimes fails.

A white blood cell cocktail containing CD4+CD25+Foxp3+ regulatory T-cells (Tregs) is required to restrain the immune system from mounting an autoaggressive systemic inflammatory response. More...
Rheumatoid arthritis is an autoimmune disorder that occurs when this protection fails and the immune system attacks the synovium, the membrane that lines all the joints of the body. It is a common disorder that causes pain, redness, and swelling around the joints. It has been estimated that approximately one percent of the adult population, worldwide, suffers from rheumatoid arthritis.

Investigators at The Wistar Institute (Philadelphia, PA; USA) used a mouse model of spontaneous autoimmune arthritis. These animals had been genetically engineered to express a “self” molecule - a clonotypic T-cell receptor (TCR) - that induced arthritis by an IL-17–dependent mechanism. The investigators then determined how TCR specificity contributed to Treg activity.

Results published in the May 1, 2012, issue of the Journal of Immunology revealed that administration of polyclonal Tregs suppressed Th17 cell formation and prevented arthritis development. Treatment with Tregs that expressed only the clonotypic TCR did not prevent development of arthritis.

“Our results show, surprisingly, that suppressing the immune response against a single target will not shut down the inflammatory response that causes rheumatoid arthritis,” said senior author Dr. Andrew J. Caton, professor in The Wistar Institute’s tumor microenvironment and metastasis program. “Instead, an array of inflammation-stimulating antigens may be involved in causing the disease, since our study shows that an array of regulatory T-cells is required to temper the immune system’s attack on joints.”

“The big unanswered question of rheumatoid arthritis is ‘why are joints targeted’?” said Dr. Caton. “Of all the tissues in the body, of all the places our immune system could attack, this question remains. One idea is that the immune system is not deliberately attacking joints in patients with rheumatoid arthritis, but the joint inflammation is a side effect of the natural tendency of these cells to accumulate in these areas of the body.”

Related Links:

The Wistar Institute



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.